早期乳腺癌超低分割全乳照射:意大利多中心观察研究
该研究纳入2020至2025年28个意大利放疗中心的2036例早期乳腺癌保乳术后患者,中位年龄70岁,均接受26 Gy/5次超低分割全乳照射。中位随访12个月,不良反应发生率低且以G1为主,提示该方案安全可行。
要点
- 26 Gy/5次超低分割全乳照射不良反应以G1为主,急性红斑最常见(37.1%)。
- 活动性吸烟和boost增加急性不良反应风险,年龄为保护因素。
- 活动性吸烟和较大boost体积与晚期不良反应风险升高相关。
核心结论
- 在2036例早期乳腺癌保乳术后患者中,26 Gy/5次超低分割全乳照射安全可行。
研究设计与样本
- 2020至2025年意大利28个放疗中心的多中心观察性研究,纳入2036例早期乳腺癌保乳术后患者,中位年龄70岁(范围19-93)。
- 所有患者接受26 Gy/5次、每次5.2 Gy的超低分割全乳照射,部分患者根据局部复发风险接受序贯或同步整合boost。
- 不良反应随访至≤2年,中位随访12个月(范围1-55)。
主要发现
- 不良反应发生率低,主要为G1;最常见急性不良反应为红斑(37.1%),其中90.2%为G1。
- 皮肤色素沉着是最常见的短期晚期不良反应,放疗结束后6个月发生率为12.2%(95.7% G1),12个月为5.7%(98.4% G1),18个月为5.7%(96% G1),24个月为4%(100% G1)。
- 多因素分析显示,活动性吸烟和boost是急性不良反应的显著因素;年龄为保护因素,较大的乳房PTV与不良反应增加相关。
- 晚期不良反应的显著危险因素为+6个月时活动性吸烟,以及+6和+12个月时较大的PTV boost。
临床怎么用
- 对早期乳腺癌保乳术后患者可考虑26 Gy/5次超低分割全乳照射,治疗前应关注吸烟状态和boost体积以评估不良反应风险。
局限性
- 中位随访仅12个月,不良反应监测≤2年,长期肿瘤学结局和晚期毒性尚未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In patients who received breast-conserving surgery for early-stage breast cancer, the present study assessed acute and short-term side effects and oncological outcomes after whole breast irradiation (WBI) with an ultrahypofractionated schedule. METHODS AND MATERIALS: From 2020 to 2025, 2036 patients (median age 70 years; range, 19-93) were recruited from 28 Italian Radiation Oncology Centers. Inclusion criteria included: early-stage breast cancer (either invasive or ductal in situ carcinomas), age ≥ 18 years, breast-conserving surgery and delivery of ultrahypofractionated WBI by means of any radiation therapy (RT) technique. All patients received 26 Gy in 5 consecutive fractions of 5.2 Gy. Depending on risk factors for local relapse, some patients received a sequential or simultaneous integrated boost. Side effects were monitored at diverse time points for ≤2 years. RESULTS: Median follow-up was 12 months (range, 1-55). The incidence of side effects was low, and they were mainly G1. The most frequent acute side effect (37.1%) was erythema, 90.2% were G1. Skin hyperpigmentation, the most frequent short-term late side effect, occurred in 12.2% of patients (95.7% G1) at 6 months, in 5.7% (98.4% G1) at 12 months, 5.7% (96% G1) at 18 months, and 4% (100% G1) at 24 months after the end of RT. In multivariate analysis, significant factors for acute side effects were active smoking and boost administration. Furthermore, age emerged as a protective factor, while a larger breast planning target volume was associated with increased side effects. Significant risk factors for late side effects were active smoking at +6 months and a larger planning target volume boost at +6 and +12 months after the end of RT. CONCLUSIONS: In our large series of patients with early-stage breast cancer, ultrahypofractionated WBI appeared safe and feasible.
引用
- Palumbo I, Becchetti AG, D'Angelo E, et al. Ultrahypofractionated Whole Breast Irradiation in Early-Stage Breast Cancer: An Italian Multicenter Observational Study. Int J Radiat Oncol Biol Phys. 2026. PMID: 42456782. doi:10.1016/j.ijrobp.2026.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。